ÔçÒÒŮѸÀ×

    1. <form id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></form>
      <address id=SSjMaZxIp><nobr id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></nobr></address>

      Biotech

      SPDR(R) S&P(R) Biotech ETF

      $93.47

      Compare similar ETFs

      Fund Size
      Dividend
      Fees
      Current
      (R) S&P(R) Biotech ETF XBI
      Fund Size
      $5.47B
      Dividend
      0.0%
      Fees
      0.35%
      Biotechnology ETF IBB
      Fund Size
      $5.98B
      Dividend
      0.3%
      Fees
      0.44%
      NYSE Arca Biotechnology Index Fund FBT
      Fund Size
      $1.12B
      Dividend
      0.7%
      Fees
      -
      ARK Genomic Revolution ETF ARKG
      Fund Size
      $955M
      Dividend
      -
      Fees
      0.75%
      Biotechnology & Genome ETF PBE
      Fund Size
      $244M
      Dividend
      0.2%
      Fees
      -
      View 7 similar ETFs →

      Average metrics of all companies in portfolio

      Compare to
      Market
      Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $30.1B
      Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. 0.25 %
      Beta Indicates the relationship between the price performance of a share and the market. 0.7858
      P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 31.96
      Negative P/E Ratio a negative P/E ratio shows that the company is not profitable, and it shows how many years it would take the company to lose its entire market capitalisation if it did not change anything -29.16
      Profitable Companies 39
      PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. 61.24
      Price to Sales Ratio Market cap divided by the revenue in the most recent year. 12.47
      Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 22.0
      Compare to
      Market
      Enterprise Value to EBIT Enterprise Value divided by EBIT -7.85
      Enterprise Value to Revenue Enterprise value divided by revenue 347.83
      Total Debt to Enterprise Value Total debt divided by enterprise value 0.08
      Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. NaN
      Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. -9577.11%
      Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. -
      Return on Equity Equity divided by market cap. 9.97%
      Return on Assets Indicates a company's profitability in relation to its total assets. -2.22%
      Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. -76.28%

      Industries

      Healthcare 87.7%
      Other 4.6%
      N/A 7.7%

      Market cap

      Micro Cap 0%
      Small Cap 18%
      Mid Cap 42%
      Large Cap 37%
      Mega Cap 3%

      130 Investments

      P/E-Ratio
      Total Investment
      Weight
      State Street Global Advisors logo

      State Street Global Advisors

      P/E-Ratio
      n/a
      Total Investment
      $357M
      Weight
      7.0%
      Alnylam Pharmaceuticals Inc logo

      ALNY - Manufacturing

      Alnylam Pharmaceuticals Inc

      P/E-Ratio
      -181.5
      Total Investment
      $147M
      Weight
      2.9%
      Insmed Inc logo

      INSM - Manufacturing

      Insmed Inc

      P/E-Ratio
      -24.9
      Total Investment
      $136M
      Weight
      2.7%
      Neurocrine Biosciences Inc logo

      NBIX - Manufacturing

      Neurocrine Biosciences Inc

      P/E-Ratio
      39.7
      Total Investment
      $134M
      Weight
      2.6%
      United Therapeutics Corp logo

      UTHR - Manufacturing

      United Therapeutics Corp

      P/E-Ratio
      11.1
      Total Investment
      $133M
      Weight
      2.6%
      Amgen Inc logo

      AMGN - Manufacturing

      Amgen Inc

      P/E-Ratio
      23.4
      Total Investment
      $132M
      Weight
      2.6%
      AbbVie Inc logo

      ABBV - Manufacturing

      AbbVie Inc

      P/E-Ratio
      98.9
      Total Investment
      $131M
      Weight
      2.6%
      Gilead Sciences Inc logo

      GILD - Manufacturing

      Gilead Sciences Inc

      P/E-Ratio
      22.3
      Total Investment
      $130M
      Weight
      2.5%
      Natera Inc logo

      NTRA - Health Care and Social Assistance

      Natera Inc

      P/E-Ratio
      -90.6
      Total Investment
      $130M
      Weight
      2.5%
      Vertex Pharmaceuticals Inc logo

      VRTX - Manufacturing

      Vertex Pharmaceuticals Inc

      P/E-Ratio
      27.6
      Total Investment
      $130M
      Weight
      2.5%
      Biogen Inc logo

      BIIB - Manufacturing

      Biogen Inc

      P/E-Ratio
      12.6
      Total Investment
      $129M
      Weight
      2.5%
      Exact Sciences Corp logo

      EXAS - Professional, Scientific, and Technical Services

      Exact Sciences Corp

      P/E-Ratio
      -8.9
      Total Investment
      $124M
      Weight
      2.4%
      Regeneron Pharmaceuticals Inc logo

      REGN - Manufacturing

      Regeneron Pharmaceuticals Inc

      P/E-Ratio
      13.7
      Total Investment
      $122M
      Weight
      2.4%
      Madrigal Pharmaceuticals Inc logo

      MDGL - Manufacturing

      Madrigal Pharmaceuticals Inc

      P/E-Ratio
      -34.5
      Total Investment
      $121M
      Weight
      2.4%
      Incyte Corp logo

      INCY - Professional, Scientific, and Technical Services

      Incyte Corp

      P/E-Ratio
      18.8
      Total Investment
      $118M
      Weight
      2.3%
      BioMarin Pharmaceutical Inc logo

      BMRN - Manufacturing

      BioMarin Pharmaceutical Inc

      P/E-Ratio
      17.0
      Total Investment
      $113M
      Weight
      2.2%
      Blueprint Medicines Corp logo

      BPMC - Manufacturing

      Blueprint Medicines Corp

      P/E-Ratio
      -52.9
      Total Investment
      $108M
      Weight
      2.1%
      Moderna Inc logo

      MRNA - Manufacturing

      Moderna Inc

      P/E-Ratio
      -3.2
      Total Investment
      $107M
      Weight
      2.1%
      Exelixis Inc logo

      EXEL - Professional, Scientific, and Technical Services

      Exelixis Inc

      P/E-Ratio
      16.9
      Total Investment
      $104M
      Weight
      2.0%
      TG Therapeutics Inc logo

      TGTX - Manufacturing

      TG Therapeutics Inc

      P/E-Ratio
      71.2
      Total Investment
      $87.8M
      Weight
      1.7%
      Halozyme Therapeutics Inc logo

      HALO - Manufacturing

      Halozyme Therapeutics Inc

      P/E-Ratio
      15.9
      Total Investment
      $86.9M
      Weight
      1.7%
      Bridgebio Pharma Inc logo

      BBIO - Manufacturing

      Bridgebio Pharma Inc

      P/E-Ratio
      -12.7
      Total Investment
      $85.6M
      Weight
      1.7%
      Sarepta Therapeutics Inc logo

      SRPT - Manufacturing

      Sarepta Therapeutics Inc

      P/E-Ratio
      -30.8
      Total Investment
      $76.2M
      Weight
      1.5%
      Cytokinetics Inc logo

      CYTK - Manufacturing

      Cytokinetics Inc

      P/E-Ratio
      -7.0
      Total Investment
      $72.6M
      Weight
      1.4%
      Revolution Medicines Inc logo

      RVMD - Manufacturing

      Revolution Medicines Inc

      P/E-Ratio
      -8.8
      Total Investment
      $70.8M
      Weight
      1.4%
      HoMEÔçÒÒŮѸÀ×